Cover Image
市場調查報告書

全球肺部疾病治療藥市場 - 全球趨勢與預測

Pulmonary Drugs Market, by Drug Class, Application, Distribution Channel, and Region - Global Trends, and Forecast till 2025

出版商 Coherent Market Insights 商品編碼 604421
出版日期 內容資訊 英文 304 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球肺部疾病治療藥市場 - 全球趨勢與預測 Pulmonary Drugs Market, by Drug Class, Application, Distribution Channel, and Region - Global Trends, and Forecast till 2025
出版日期: 2018年02月08日 內容資訊: 英文 304 Pages
簡介

本報告提供全球肺部疾病治療藥市場相關調查,市場現狀與今後發展趨勢,各市場區隔趨勢,及主要加入企業的簡介等彙整資料。

第1章 與調查目的假設

第2章 市場概要

第3章 市場趨勢,法律規章,趨勢分析

  • 市場趨勢
  • 法律規章方案
  • 開發平台分析
  • 推銷活動和宣傳活動
  • 供應鏈分析
  • PEST分析
  • 流行病學

第4章 各類藥物市場

  • 簡介
  • 吸入型類固醇
  • 長期作用型β2促效劑
  • 抗組織胺藥物
  • 血管擴張劑
  • 其他

第5章 各用途市場

  • 簡介
  • 氣喘、COPD
  • 過敏性鼻炎
  • 肺動脈高血壓
  • 囊狀纖維化症
  • 其他

第6章 各流通管道市場

  • 簡介
  • 院內藥局
  • 零售藥局
  • 電子商務

第7章 各地區市場

  • 簡介
  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第8章 競爭環境

  • 熱圖分析
  • 市場佔有率分析
  • 企業簡介
  • 分析師的見解

第9章 章節

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

The pulmonary drugs are used for treating the conditions affecting lungs. The pulmonary drugs are used from treating minor illnesses such as the common cold to cure long-term disorders such asthma. These agents are available in different forms such as oral tablets, oral liquids, and injections or inhalations. Inhalations deliver the medicine directly to the lungs, which can act directly on the lung tissues, minimizing systemic side effects.

Market Dynamics

The major factors driving growth of the pulmonary drugs market include increasing incidence of chronic respiratory diseases, tobacco smoking, and government and non-government initiatives. According to Center for Disease Control and Prevention (CDC), in 2015, 25 million people in the U.S. suffered from asthma that is 1 in 13 Americans were suffering from asthma. Under 18 years of age, 6.2 million people suffered from asthma. Annually asthma accounts for 14.2 million physician office visits and 1.8 million emergency visits. Moreover, the significant number of patent expiration of branded drugs, funding for research and development and launch of innovative products are expected to contribute as major factors in the market growth over the forecast period. For instance, in 2017, GSK received U.S. FDA approval for unique three-in-one inhaler named Trelegy Ellipta for chronic lung disease. Trelegy Ellipta combines three therapies into a single inhaler, thereby giving a new treatment option to the patients. However, a large undiagnosed population and side effects associated with the consumption of these drugs resulting into kidney problems leading to adverse outcomes are expected to limit the market growth.  

Key features of the study:

This report provides in-depth analysis of pulmonary drugs market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2017 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players

It profiles leading players in the global pulmonary drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, and strategies, and future plans

Key companies covered as a part of this study include Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZeneca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi Farmaceuticals S.p.A, Zambon Company S.p.A, Alaxia SAS, and Merck Sharp & Dohme Limited

Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics

The global pulmonary drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the pulmonary drugs market

Detailed Segmentation:

  • Global Pulmonary Drugs Market, By Drug Class:
  • Inhaled Corticosteroids
  • Long Acting Beta-2 Agonists
  • Antihistamines
  • Vasodilators
  • Short Acting Beta-2 Agonists
  • Others
  • Global Pulmonary Drugs Market, By Application:
  • Asthma & COPD
  • Allergic Rhinitis
  • Pulmonary Arterial Hypertension
  • Cystic Fibrosis
  • Others
  • Global Pulmonary Drugs Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce
  • Global Pulmonary Drugs Market, By Geography:
  • North America
  • By Drug Class:
  • Inhaled Corticosteroids
  • Long Acting Beta-2 Agonists
  • Antihistamines
  • Vasodilators
  • Short Acting Beta-2 Agonists
  • Others
  • By Application:
  • Asthma & COPD
  • Allergic Rhinitis
  • Pulmonary Arterial Hypertension
  • Cystic Fibrosis
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce
  • By Country:
  • U.S.
  • Canada
  • Latin America
  • By Drug Class:
  • Inhaled Corticosteroids
  • Long Acting Beta-2 Agonists
  • Antihistamines
  • Vasodilators
  • Short Acting Beta-2 Agonists
  • Others
  • By Application:
  • Asthma & COPD
  • Allergic Rhinitis
  • Pulmonary Arterial Hypertension
  • Cystic Fibrosis
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce
  • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • By Drug Class:
  • Inhaled Corticosteroids
  • Long Acting Beta-2 Agonists
  • Antihistamines
  • Vasodilators
  • Short Acting Beta-2 Agonists
  • Others
  • By Application:
  • Asthma & COPD
  • Allergic Rhinitis
  • Pulmonary Arterial Hypertension
  • Cystic Fibrosis
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce
  • By Country:
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • By Drug Class:
  • Inhaled Corticosteroids
  • Long Acting Beta-2 Agonists
  • Antihistamines
  • Vasodilators
  • Short Acting Beta-2 Agonists
  • Others
  • By Application:
  • Asthma & COPD
  • Allergic Rhinitis
  • Pulmonary Arterial Hypertension
  • Cystic Fibrosis
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce
  • By Country:
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • By Drug Class:
  • Inhaled Corticosteroids
  • Long Acting Beta-2 Agonists
  • Antihistamines
  • Vasodilators
  • Short Acting Beta-2 Agonists
  • Others
  • By Application:
  • Asthma & COPD
  • Allergic Rhinitis
  • Pulmonary Arterial Hypertension
  • Cystic Fibrosis
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • By Drug Class:
  • Inhaled Corticosteroids
  • Long Acting Beta-2 Agonists
  • Antihistamines
  • Vasodilators
  • Short Acting Beta-2 Agonists
  • Others
  • By Application:
  • Asthma & COPD
  • Allergic Rhinitis
  • Pulmonary Arterial Hypertension
  • Cystic Fibrosis
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce
  • By Country:
  • South Africa
  • Central Africa
  • North Africa
  • Company Profiles
  • Sanofi SA*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
  • Meda Pharmaceuticals
  • Circassia Pharmaceuticals Plc.
  • AstraZeneca Plc.
  • GlaxoSmithKline Plc.
  • Mallinckrodt Pharmaceuticals Plc.
  • Cheisi Farmaceutici S.p.A
  • Zambon Company S.p.A
  • Alaxia SAS
  • Merck Sharp & Dohme Limited
  • “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Application
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
    • Market Trends
  • Regulatory Scenario
  • Pipeline Analysis
  • Promotional Activities and Campaigns
  • Supply Chain Analysis
  • PEST Analysis
  • Epidemiology

4. Global Pulmonary Drugs Market, By Drug Class, 2017 - 2025, (US$ Million)

  • Introduction
    • Market Share Analysis, 2016 and 2025 (%)
    • Y-o-Y Growth Analysis, 2017 - 2025
    • Segment Trends
  • Inhaled Corticosteroids
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
  • Long Acting Beta-2 Agonists
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
  • Antihistamines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
  • Vasodilators
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
  • Short Acting Beta-2 Agonists
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)

5. Global Pulmonary Drugs Market, By Application, 2017 - 2025, (US$ Million)

  • Introduction
    • Market Share Analysis, 2016 and 2025 (%)
    • Y-o-Y Growth Analysis, 2017 - 2025
    • Segment Trends
  • Asthma & COPD
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
  • Allergic Rhinitis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
  • Pulmonary Arterial Hypertension
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
  • Cystic Fibrosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)

6. Global Pulmonary Drugs Market, By Distribution Channel, 2017 - 2025, (US$ Million)

  • Introduction
    • Market Share Analysis, 2016 and 2025 (%)
    • Y-o-Y Growth Analysis, 2017 - 2025
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
  • E-Commerce
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)

7. Global Pulmonary Drugs Market, By Region, 2017 - 2025, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2016 and 2025 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017 - 2025
  • North America
    • Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of APAC
  • Middle East
    • Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
    • South Africa
    • Central Africa
    • North Africa

8. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis (3x3 Matrix)
  • Company Profiles
    • Sanofi SA*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Meda Pharmaceuticals
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Circassia Pharmaceuticals Plc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • AstraZeneca Plc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • GlaxoSmithKline Plc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Mallinckrodt Pharmaceuticals Plc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Cheisi Farmaceutici S.p.A
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Zambon Company S.p.A
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Alaxia SAS
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Merck Sharp & Dohme Limited
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
  • Analyst Views

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact

Browse 50 market data tables and 38 figures on "Pulmonary Drugs Market - Global forecast to 2025".

Back to Top